• Richard J. Knox
  • Roger G. Melton


In the 197Os it was thought that the advent of monoclonal antibody technology heralded the fruition of the search for the “magic bullet” first proposed by Ehrlich in the early years of this century (Ehrlich, 1960). In practice, however, this goal has remained elusive as a range of obstacles have presented themselves and have proved very difficult to overcome. To date, there have been numerous attempts to improve the cytotoxicity of the antibody “missile” by attaching a variety of “warheads” to them, for example, cytotoxic drugs, such as adriamycin or methotrexate, toxins, such as ricin A-chain or Pseudomonas exotoxin, and radioisotopes (Pietersz and McKenzie, 1992).


Catalytic Antibody Blood Ratio Human Small Cell Lung Cancer Prodrug Activation Antibody Direct Enzyme Prodrug Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bagshawe, K. D., 1989, Towards generating cytotoxic agents at cancer sites, Br. J. Cancer 60:275–281.PubMedCrossRefGoogle Scholar
  2. Bagshawe, K. D., and Sharma, S. K., 1996, Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT, Transplant. Proc. 28:3156–3158.PubMedGoogle Scholar
  3. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G. T., Burke, P. J., Melton, R. G., and Sherwood, R. F., 1991, Antibody Directed Enzyme Prodrug Therapy (ADEPT)—clinical report, Disease Marker 9:233–238.Google Scholar
  4. Begent, R. H. J., 1985, Recent advances in tumour imaging: Use of radiolabelled monoclonal antibodies, Biochim. Biophys. Acta 780:151–166.PubMedGoogle Scholar
  5. Bosslet, K., Czech, J., and Hoffmann, D., 1994, Tumor-selective prodrug activation by fusion protein-mediated catalysis, Cancer Res. 54:2151–2159.PubMedGoogle Scholar
  6. Campbell, D. A., Gong, B., Kochersperger, L. M., Yonkovich, S., Gallop, M. A., and Schultz, P. G., 1994, Antibody-catalyzed prodrug activation, J. Am. Chem. Soc. 116:2165–2166.CrossRefGoogle Scholar
  7. Cobb, L. M., Humphreys, J. A., and Harrison, A., 1987, The diffusion of a tumour-specific monoclonal antibody in lymphoma infiltrated spleen, Br. J. Cancer 55:53–55.PubMedCrossRefGoogle Scholar
  8. Desutter, K. and Fiers, W. A., 1994, Bifunctional murine-human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase. Mol. Immunol. 31:261–267.CrossRefGoogle Scholar
  9. Ehrlich, P. The Collected Papers of P. Ehrlich, Pergamon Press, London, 1960, pp. 505–518.Google Scholar
  10. Fargion, S., Carney, D., Mulshine, J., Rosen, S., Bunn, P., Jewitt, P., Cuttitta, F., Gazdar, A., and Minna, J., 1986, Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies, Cancer Res. 46:2633–2638.PubMedGoogle Scholar
  11. Frei, E. III, Teicher, B. A., Holden, S. A., Cathcart, K. N. S., and Wang, Y., 1988, Preclinical studies and clinical correlation of the effect of alkylating dose, Cancer Res. 48:6417–6423.PubMedGoogle Scholar
  12. Goldenberg, D. M., Sharkey, R. M., Hall, T. C., Murthy, S., Siegal, J. A., Izon, D. O., Swayne, L. C., Lake, D., Hansen, H. J., and Pinsky, M., 1991, Radioimmunotherapy of B-cell lymphomas with 131I-labeled LL2 (EPB-2) monoclonal antibody, Antibody Immunoconj. Radiopharm. 4: 763–769.Google Scholar
  13. Goshorn, S. C., Svensson, H. P., Kerr, D. E., Somerville, J. E., Senter, P. D., and Fell, H. P., 1993, Genetic construction, expression, and characterization of a single chain anticarcinoma antibody fused to ß-lactamase, Cancer Res. 53:2123–2127.PubMedGoogle Scholar
  14. Haenseler, E., Esswein, A., Vitols, K. S., Montejano, Y., Mueller, B. M., Reisfeld, R. A., and Huennekens, E. M., 1992, Activation of methotrexate-alpha-alanine by carboxypeptidase-A monoclonal antibody conjugate, Biochemistry 31:891–897.PubMedCrossRefGoogle Scholar
  15. Melton, R. G., Rowland, J. A., Pietersz, G. A., Sherwood, R. E, and McKenzie, I. E C., 1993, Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase-G2 conjugate, Eur. J. Cancer 29A:1177–1183.PubMedCrossRefGoogle Scholar
  16. Melton, R. G., 1996, Preparation and purification of antibody-enzyme conjugates for therapeutic applications, Adv. Drug Delivery Rev. 22:289–301.CrossRefGoogle Scholar
  17. Meredith, R. E, Khazaeli, M. B., Pion, W. E., Liu, T., Russell, C. D., Wheeler, R. H., and Lobuglio, A. E, 1993, Effect of human immune response on repeat courses of131í-chimeric B72.3 antibody therapy, Antibody Immunoconj. Radiopharm. 6:39–46.Google Scholar
  18. Moshakis, V., Mcllhinney, R. A. J., and Neville, A. M., 1981, Cellular distribution of monoclonal antibody in human tumours after I.V. administration, Br. J. Cancer 44:663–669.PubMedCrossRefGoogle Scholar
  19. Natali, P. G., Cavaliere, R., Bigotti, A., Nicotra, M. R., Russo, C., Ng, A. K., Giacomini, P., and Ferrone, S. (1983), Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions, J. Immunol. 130:1462–1466.PubMedGoogle Scholar
  20. Neuberger, M. S., Williams, G. T., and Fox, R. 0., 1984, Recombinant antibodies possessing novel effector functions, Nature 312:604–608.PubMedCrossRefGoogle Scholar
  21. Pietersz, G. A. and McKenzie, I. F. C., 1992, Antibody conjugates for the treatment of cancer, Immunol. Rev. 129:57–80.PubMedCrossRefGoogle Scholar
  22. Rogers, G. T., Burke, P. J., Sharma, S. K., Koodie, R., and Boden, J. A., 1995, Plasma clearance of an antibody-enzyme conjugate in ADEPT by monoclonal anti-enzyme: Its effect on prodrug activation in vivo, Br. J. Cancer 72:1357–1363.PubMedCrossRefGoogle Scholar
  23. Sehon, A. H., 1991, Carl Prausnitz Memorial Lecture—Suppression of antibody responses by chemically modified antigens, Int. Arch. Allergy Appl. Immunol. 94:11–20.PubMedCrossRefGoogle Scholar
  24. Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, J. A., Rogers, G. T, Springer, C. J., Melton, R. G., and Sherwood, R. F., 1994, Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy, Cancer 73:1114–1120.PubMedCrossRefGoogle Scholar
  25. Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, J. A., and Rogers, G. T., 1990, Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model, Br. J. Cancer 61:659–662.PubMedCrossRefGoogle Scholar
  26. Sharma, S. K., Bagshawe, K. D., Melton, R. G., and Begent, R. H. J., 1996, Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT, Transplant. Proc. 28:3154–3155.PubMedGoogle Scholar
  27. Sharma, S. K., Bagshawe, K. D., Melton, R. G., and Sherwood, R. F., 1992, Human immune response to monoclonal antibody-enzyme conjugates in ADEPT, Cell Biophys. 21:109–120.PubMedGoogle Scholar
  28. Shepherd, T. A., Jungheim, L. N., Meyer, D. L., and Starling, J. K., 1991, A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody 3-lactamase conjugate for the treatment of cancer, Bioorg. Medicinal Chem. Let. 1:21–26.CrossRefGoogle Scholar
  29. Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., Antoniw, P., Burke, R J., Rogers, G. T., Sherwood, R. Y., and Melton, R. G., 1991, Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds, Eur. J. Cancer 27:1361–1366.PubMedCrossRefGoogle Scholar
  30. Stevenson, G. T. and Stevenson, E K., 1975, Antibody to a molecularly defined antigen confined to a tumour cell surface, Nature 254:714–716.PubMedCrossRefGoogle Scholar
  31. Tagliabue, E., Porro, G., Barbanti, P., Tone, G. D., Menard, S., Rilke, E, Cerasoli, S., and Colnaghi, M. I., 1986, Improvement of tumor cell detection using a pool of monoclonal antibodies, Hybridoma 5:107–115.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Richard J. Knox
    • 1
  • Roger G. Melton
    • 2
  1. 1.Department of Medical OncologyCharing Cross HospitalLondonUK
  2. 2.Enzacta Ltd.SalisburyUK

Personalised recommendations